Interpretation of <i>the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody</i>_Chinese Journal of Ocular Fundus Diseases

Authors：

Wang Xizi ¹ , Zheng Wenjie ² ,  Zhang Xiaomin ¹

1. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China;
2. Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China;

Corresponding author：

Zhang Xiaomin, Email: xzhang08@tmu.edu.cn

Keywords：

Anti-tumor necrosis factor-α monoclonal antibody; Non-infectious uveitis; Expert consensus; Interpretation

DOI：

10.3760/cma.j.cn511434-20240104-00005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

As a new treatment option after conventional corticosteroids and immunomodulatory drugs, biologics have been widely used in the clinical management of non-infectious uveitis in many countries due to their approved efficacy and safety. Anti-tumor necrosis factor-alpha monoclonal antibody is the most commonly used one. However, the guidance on its standardized application is lacking. The Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association compiled the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody. This evidence-based consensus is made according to the principle of consensus building and combines the clinical experience of the experts. Twelve recommendations are formatted on the application of Adalimumab and Infliximab. The interpretation of this consensus point will help improve the normative and effective application of anti-tumor necrosis factor-alpha monoclonal antibody in ophthalmologists, rheumatologists and immunologists.

Citation： Wang Xizi, Zheng Wenjie, Zhang Xiaomin. Interpretation of the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody. Chinese Journal of Ocular Fundus Diseases, 2024, 40(1): 20-26. doi: 10.3760/cma.j.cn511434-20240104-00005 Copy

1.	Valenzuela RA, Flores I, Urrutia B, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A Minireview[J/OL]. Front Pharmacol, 2020, 11: 655[2020-05-08]. https://pubmed.ncbi.nlm.nih.gov/32508634/. DOI: 10.3389/fphar.2020.00655.
2.	Jiang Q, Li Z, Tao T, et al. TNF-α in uveitis: from bench to clinic[J/OL]. Front Pharmacol, 2021, 12: 740057[2021-11-02]. https://pubmed.ncbi.nlm.nih.gov/34795583/. DOI: 10.3389/fphar.2021.740057.
3.	Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719. DOI: 10.3390/ijms22052719.
4.	海峡两岸医药卫生交流协会风湿免疫分会眼免疫学组. 抗肿瘤坏死因子-α单克隆抗体治疗非感染性葡萄膜炎中国专家共识[J]. 中华眼底病杂志, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.
5.	Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and Etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2007, 66(4): 548-550. DOI: 10.1136/ard.2006.058248.
6.	Marotte H, Cimaz R. Etanercept-TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?[J]. Expert Opin Biol Ther, 2014, 14(5): 569-572. DOI: 10.1517/14712598.2014.896334.
7.	Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review[J/OL]. Front Med (Lausanne), 8: 695904[2021-09-10]. https://pubmed.ncbi.nlm.nih.gov/34568364/. DOI: 10.3389/fmed.2021.695904.
8.	Leone GM, Mangano K, Petralia MC, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630. DOI: 10.3390/jcm12041630.
9.	Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932-943. DOI: 10.1056/NEJMoa1509852.
10.	Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10050): 1183-1192. DOI: 10.1016/S0140-6736(16)31339-3.
11.	Yang P, Zhong Z, Du L, et al. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis[J]. Br J Ophthalmol, 2021, 105(1): 75-82. DOI: 10.1136/bjophthalmol-2020-315960.
12.	李雁, 文小凤, 魏来. 非感染性葡萄膜炎343例患者的分型、临床表现及并发症[J]. 眼科新进展, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.Li Y, Wen XF, Wei L. Classification, clinical manifestations and complications of 343 non-infectious uveitis patients[J]. Rec Adv Ophthalmol, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.
13.	Yang S, Tao T, Huang Z, et al. Adalimumab in Vogt-Koyanagi-Harada disease refractory to conventional therapy[J/OL]. Front Med (Lausanne), 2022, 8: 799427[2022-01-12]. https://pubmed.ncbi.nlm.nih.gov/35096888/. DOI: 10.3389/fmed.2021.799427.
14.	Nakai S, Takeuchi M, Usui Y, et al. Efficacy and safety of Adalimumab for exacerbation or relapse of ocular inflammation in patients with Vogt-Koyanagi-Harada disease: a multicenter study[J]. Ocul Immunol Inflamm, 2022, 24: 1-9. DOI: 10.1080/09273948.2022.2092007.
15.	Rahman N, Artiaga JCM, Bouras K, et al. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature[J]. J Ophthalmic Inflamm Infect, 2023, 13(1): 27. DOI: 10.1186/s12348-023-00333-6.
16.	Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease[J]. Nat Commun, 2023, 14(1): 3768. DOI: 10.1038/s41467-023-39483-5.
17.	中华医学会眼科学分会眼免疫学组, 中国医师协会眼科医师分会葡萄膜炎与免疫学组. 中国福格特-小柳-原田综合征临床诊疗专家共识(2023年)[J]. 中华眼科杂志, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association; Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Vogt-Koyanagi-Harada syndrome (2023)[J]. Chin J Ophthalmol, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.
18.	Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490. DOI: 10.1080/14712598.2019.1595578.
19.	van der Houwen T, van Laar J. Behҫet's disease, and the role of TNF-α and TNF-α blockers[J]. Int J Mol Sci, 2020, 21(9): 3072. DOI: 10.3390/ijms21093072.
20.	Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Behçet's disease[J]. Orphanet J Rare Dis, 2021, 16(Suppl 1): S352. DOI: 10.1186/s13023-020-01620-4.
21.	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. DOI: 10.1136/annrheumdis-2018-213225.
22.	Karadag O, Bolek EC. Management of Behcet's syndrome[J]. Rheumatology (Oxford), 2020, 59(Suppl 3): Siii108-iii117. DOI: 10.1093/rheumatology/keaa086.
23.	Aboul Naga SH, Hassan LM, El Zanaty RT, et al. Behçet uveitis: current practice and future perspectives[J/OL]. Front Med (Lausanne), 2022, 9: 968345[2022-09-07]. https://pubmed.ncbi.nlm.nih.gov/36160151/. DOI: 10.3389/fmed.2022.968345.
24.	Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet's disease following withdrawal of successful anti-tumor necrosis factor treatment[J]. Arthritis Rheumatol, 2017, 69(12): 2380-2385. DOI: 10.1002/art.40235.
25.	Sener H, Evereklioglu C, Horozoglu F, et al. Efficacy and safety of Adalimumab in patients with Behçet uveitis: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2023, 10: 1-9. DOI: 10.1080/09273948.2022.2157288.
26.	Yang S, Huang Z, Hu Y, et al. The efficacy of Adalimumab as an initial treatment in patients with Behçet's retinal vasculitis[J/OL]. Front Pharmacol, 2021, 12: 609148[2021-06-22]. https://pubmed.ncbi.nlm.nih.gov/34239438/. DOI: 10.3389/fphar.2021.609148.
27.	中华医学会眼科学分会眼免疫学组, 中国医师协会眼科医师分会葡萄膜炎与免疫学组. 中国白塞综合征性葡萄膜炎临床诊疗专家共识(2023年)[J]. 中华眼科杂志, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association, Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Behcet′s uveitis (2023)[J]. Chin J Ophthalmol, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.
28.	程卫东, 张美芬. 儿童非感染性葡萄膜炎药物治疗研究进展[J]. 中华眼科杂志, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.Chen WD, Zhang MF. Research progress of medication treatment of pediatric noninfectious uveitis[J]. Chin J Ophthalmol, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.
29.	中华医学会儿科学分会免疫学组, 中国儿童风湿免疫病联盟, 国家儿童健康与疾病临床研究中心风湿免疫联盟. 幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)[J]. 协和医学杂志, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.Immunology Group, Pediatrics Branch of Chinese Medical Association, China Children's Rheumatology Alliance, National Clinical Research Center for Child Health and Disease Rheumatology Alliance. Chinese expert consensus on juvenile idiopathic arthritis-associated uveitis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.
30.	Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management[J]. Biomedicines, 2023, 11(2): 629. DOI: 10.3390/biomedicines11020629.
31.	Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
32.	Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors[J]. J Rheumatol, 2013, 40(8): 1394-1403. DOI: 10.3899/jrheum.121180.
33.	Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
34.	Solebo AL, Rahi JS, Dick AD, et al. Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK[J]. Br J Ophthalmol, 2020, 104(1): 11-16. DOI: 10.1136/bjophthalmol-2018-313789.
35.	Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-term follow-up of patients with uveitis treated with Adalimumab: response rates and reasons for discontinuation of therapy[J]. Am J Ophthalmol, 2022, 240: 194-204. DOI: 10.1016/j.ajo.2022.03.017.
36.	Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244-279. DOI: 10.1016/j.pharmthera.2007.10.001.
37.	Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with Adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
38.	Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
39.	Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
40.	Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies[J]. Ophthalmology, 2016, 123(12): 2618-2625. DOI: 10.1016/j.ophtha.2016.08.025.
41.	Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations[J]. Clin Rheumatol, 2018, 37(5): 1407-1411. DOI: 10.1007/s10067-018-4057-7.
42.	Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Behçet's disease[J]. Ophthalmology, 2018, 125(9): 1444-1451. DOI: 10.1016/j.ophtha.2018.02.020.
43.	Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of Infliximab in refractory uveitis due to Behçet disease: national study of 103 white patients[J]. J Rheumatol, 2021, 48(5): 741-750. DOI: 10.3899/jrheum.200300.
44.	Salido Olivares M, Loza Santamaría E. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: systematic review[J/OL]. Semin Arthritis Rheum, 2022, 52: 151944[2022-01-02]. https://pubmed.ncbi.nlm.nih.gov/35027247/. DOI: 10.1016/j.semarthrit.2021.11.010.
45.	Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives[J]. Lancet Gastroenterol Hepatol, 2022, 7(2): 171-185. DOI: 10.1016/S2468-1253(21)00223-5.
46.	Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis[J]. Clin Rheumatol, 2018, 37(2): 549-553. DOI: 10.1007/s10067-017-3890-4.
47.	Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis[J]. J Rheumatol, 2013, 40(10): 1749-1755. DOI: 10.3899/jrheum.130133.
48.	Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease[J]. Ann Rheum Dis, 2013, 72(4): 517-524. DOI: 10.1136/annrheumdis-2011-201244.
49.	Namba K, Kaburaki T, Tsuruga H, et al. Long-term safety and effectiveness of Adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 patients[J]. Ophthalmol Ther, 2022, 11(3): 1147-1161. DOI: 10.1007/s40123-022-00493-z.
50.	Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring[J]. Joint Bone Spine, 2011, 78(Suppl 1): S15-185. DOI: 10.1016/S1297-319X(11)70001-X.
51.	谭雨亭, 侍效春, 刘晓清. 应用肿瘤坏死因子拮抗剂人群结核潜伏感染的检测及预防性治疗[J]. 协和医学杂志, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.Tan YT, Shi XC, Liu XQ. Testing and prophylaxis of latent tuberculosis infection in patients receiving tumor necrosis factor-α antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.
52.	Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2): S10-20. DOI: 10.1016/j.cmi.2017.12.025.
53.	池滢, 杨柳. 关注TNF-α抑制剂在葡萄膜炎治疗中存在的感染和肿瘤发生及进展风险[J]. 中华实验眼科杂志, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.Chi Y, Yang L. Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis[J]. Chin J Pract Ophthalmol, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.
54.	肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.Expert Recommendation Group on the Use of Tumor Necrosis Factor Antagonists in Tuberculosis Prevention and Management. Expert consensus on the use of tumor necrosis factor antagonists in tuberculosis prevention and management[J]. Chin J Rheumat, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.
55.	王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.Wang GQ, Duan ZP, Wang FS, et al. The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. J Prac Hepatol, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.
56.	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识(2019)[J]. 中华皮肤科杂志, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.Chinese Medical Association Dermatology and venereology Branch, Chinese Medical Doctor Association Dermatology Branch, Chinese Association of Integrated Traditional and Western Medicine Dermatology and venereology Professional Committee. Treatment of psoriasis with biological agents: a Chinese expert consensus statement (2019)[J]. Chin J Dermat, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.
57.	Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies[J/OL]. Front Neurol, 2022, 13: 1003270[2022-09-29]. https://pubmed.ncbi.nlm.nih.gov/36247761/. DOI: 10.3389/fneur.2022.1003270.
58.	李莉, 杨卓, 杨佳, 等. 基于FAERS的阿达木单抗相关不良事件风险信号挖掘[J]. 中国药房, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.Li L, Yang Z, Yang J, et al. Risk signal mining of adverse event related to adalimumab based on FAERS[J]. China Pharmacy, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.

1. Valenzuela RA, Flores I, Urrutia B, et al. New pharmacological strategies for the treatment of non-infectious uveitis. A Minireview[J/OL]. Front Pharmacol, 2020, 11: 655[2020-05-08]. https://pubmed.ncbi.nlm.nih.gov/32508634/. DOI: 10.3389/fphar.2020.00655.
2. Jiang Q, Li Z, Tao T, et al. TNF-α in uveitis: from bench to clinic[J/OL]. Front Pharmacol, 2021, 12: 740057[2021-11-02]. https://pubmed.ncbi.nlm.nih.gov/34795583/. DOI: 10.3389/fphar.2021.740057.
3. Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719. DOI: 10.3390/ijms22052719.
4. 海峡两岸医药卫生交流协会风湿免疫分会眼免疫学组. 抗肿瘤坏死因子-α单克隆抗体治疗非感染性葡萄膜炎中国专家共识[J]. 中华眼底病杂志, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-00473.
5. Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and Etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2007, 66(4): 548-550. DOI: 10.1136/ard.2006.058248.
6. Marotte H, Cimaz R. Etanercept-TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?[J]. Expert Opin Biol Ther, 2014, 14(5): 569-572. DOI: 10.1517/14712598.2014.896334.
7. Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review[J/OL]. Front Med (Lausanne), 8: 695904[2021-09-10]. https://pubmed.ncbi.nlm.nih.gov/34568364/. DOI: 10.3389/fmed.2021.695904.
8. Leone GM, Mangano K, Petralia MC, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630. DOI: 10.3390/jcm12041630.
9. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932-943. DOI: 10.1056/NEJMoa1509852.
10. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10050): 1183-1192. DOI: 10.1016/S0140-6736(16)31339-3.
11. Yang P, Zhong Z, Du L, et al. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis[J]. Br J Ophthalmol, 2021, 105(1): 75-82. DOI: 10.1136/bjophthalmol-2020-315960.
12. 李雁, 文小凤, 魏来. 非感染性葡萄膜炎343例患者的分型、临床表现及并发症[J]. 眼科新进展, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.Li Y, Wen XF, Wei L. Classification, clinical manifestations and complications of 343 non-infectious uveitis patients[J]. Rec Adv Ophthalmol, 2021, 41(7): 673-675. DOI: 10.13389/j.cnki.rao.2021.0139.
13. Yang S, Tao T, Huang Z, et al. Adalimumab in Vogt-Koyanagi-Harada disease refractory to conventional therapy[J/OL]. Front Med (Lausanne), 2022, 8: 799427[2022-01-12]. https://pubmed.ncbi.nlm.nih.gov/35096888/. DOI: 10.3389/fmed.2021.799427.
14. Nakai S, Takeuchi M, Usui Y, et al. Efficacy and safety of Adalimumab for exacerbation or relapse of ocular inflammation in patients with Vogt-Koyanagi-Harada disease: a multicenter study[J]. Ocul Immunol Inflamm, 2022, 24: 1-9. DOI: 10.1080/09273948.2022.2092007.
15. Rahman N, Artiaga JCM, Bouras K, et al. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature[J]. J Ophthalmic Inflamm Infect, 2023, 13(1): 27. DOI: 10.1186/s12348-023-00333-6.
16. Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease[J]. Nat Commun, 2023, 14(1): 3768. DOI: 10.1038/s41467-023-39483-5.
17. 中华医学会眼科学分会眼免疫学组, 中国医师协会眼科医师分会葡萄膜炎与免疫学组. 中国福格特-小柳-原田综合征临床诊疗专家共识(2023年)[J]. 中华眼科杂志, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association; Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Vogt-Koyanagi-Harada syndrome (2023)[J]. Chin J Ophthalmol, 2023, 59(7): 518-525. DOI: 10.3760/cma.j.cn112142-20230313-00098.
18. Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490. DOI: 10.1080/14712598.2019.1595578.
19. van der Houwen T, van Laar J. Behҫet's disease, and the role of TNF-α and TNF-α blockers[J]. Int J Mol Sci, 2020, 21(9): 3072. DOI: 10.3390/ijms21093072.
20. Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Behçet's disease[J]. Orphanet J Rare Dis, 2021, 16(Suppl 1): S352. DOI: 10.1186/s13023-020-01620-4.
21. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. DOI: 10.1136/annrheumdis-2018-213225.
22. Karadag O, Bolek EC. Management of Behcet's syndrome[J]. Rheumatology (Oxford), 2020, 59(Suppl 3): Siii108-iii117. DOI: 10.1093/rheumatology/keaa086.
23. Aboul Naga SH, Hassan LM, El Zanaty RT, et al. Behçet uveitis: current practice and future perspectives[J/OL]. Front Med (Lausanne), 2022, 9: 968345[2022-09-07]. https://pubmed.ncbi.nlm.nih.gov/36160151/. DOI: 10.3389/fmed.2022.968345.
24. Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet's disease following withdrawal of successful anti-tumor necrosis factor treatment[J]. Arthritis Rheumatol, 2017, 69(12): 2380-2385. DOI: 10.1002/art.40235.
25. Sener H, Evereklioglu C, Horozoglu F, et al. Efficacy and safety of Adalimumab in patients with Behçet uveitis: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2023, 10: 1-9. DOI: 10.1080/09273948.2022.2157288.
26. Yang S, Huang Z, Hu Y, et al. The efficacy of Adalimumab as an initial treatment in patients with Behçet's retinal vasculitis[J/OL]. Front Pharmacol, 2021, 12: 609148[2021-06-22]. https://pubmed.ncbi.nlm.nih.gov/34239438/. DOI: 10.3389/fphar.2021.609148.
27. 中华医学会眼科学分会眼免疫学组, 中国医师协会眼科医师分会葡萄膜炎与免疫学组. 中国白塞综合征性葡萄膜炎临床诊疗专家共识(2023年)[J]. 中华眼科杂志, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.Ocular Immunology Group, Ophthalmology Branch, Chinese Medical Association, Uveitis and Immunology Group, Ophthalmology Branch, Chinese Medical Doctor Association. Chinese expert consensus on the clinical diagnosis and treatment of Behcet′s uveitis (2023)[J]. Chin J Ophthalmol, 2023, 59(8): 611-619. DOI: 10.3760/cma.j.cn112142-20230404-00137.
28. 程卫东, 张美芬. 儿童非感染性葡萄膜炎药物治疗研究进展[J]. 中华眼科杂志, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.Chen WD, Zhang MF. Research progress of medication treatment of pediatric noninfectious uveitis[J]. Chin J Ophthalmol, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.
29. 中华医学会儿科学分会免疫学组, 中国儿童风湿免疫病联盟, 国家儿童健康与疾病临床研究中心风湿免疫联盟. 幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)[J]. 协和医学杂志, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.Immunology Group, Pediatrics Branch of Chinese Medical Association, China Children's Rheumatology Alliance, National Clinical Research Center for Child Health and Disease Rheumatology Alliance. Chinese expert consensus on juvenile idiopathic arthritis-associated uveitis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.
30. Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management[J]. Biomedicines, 2023, 11(2): 629. DOI: 10.3390/biomedicines11020629.
31. Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
32. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors[J]. J Rheumatol, 2013, 40(8): 1394-1403. DOI: 10.3899/jrheum.121180.
33. Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
34. Solebo AL, Rahi JS, Dick AD, et al. Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK[J]. Br J Ophthalmol, 2020, 104(1): 11-16. DOI: 10.1136/bjophthalmol-2018-313789.
35. Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-term follow-up of patients with uveitis treated with Adalimumab: response rates and reasons for discontinuation of therapy[J]. Am J Ophthalmol, 2022, 240: 194-204. DOI: 10.1016/j.ajo.2022.03.017.
36. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244-279. DOI: 10.1016/j.pharmthera.2007.10.001.
37. Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with Adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
38. Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
39. Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
40. Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies[J]. Ophthalmology, 2016, 123(12): 2618-2625. DOI: 10.1016/j.ophtha.2016.08.025.
41. Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations[J]. Clin Rheumatol, 2018, 37(5): 1407-1411. DOI: 10.1007/s10067-018-4057-7.
42. Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Behçet's disease[J]. Ophthalmology, 2018, 125(9): 1444-1451. DOI: 10.1016/j.ophtha.2018.02.020.
43. Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of Infliximab in refractory uveitis due to Behçet disease: national study of 103 white patients[J]. J Rheumatol, 2021, 48(5): 741-750. DOI: 10.3899/jrheum.200300.
44. Salido Olivares M, Loza Santamaría E. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: systematic review[J/OL]. Semin Arthritis Rheum, 2022, 52: 151944[2022-01-02]. https://pubmed.ncbi.nlm.nih.gov/35027247/. DOI: 10.1016/j.semarthrit.2021.11.010.
45. Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives[J]. Lancet Gastroenterol Hepatol, 2022, 7(2): 171-185. DOI: 10.1016/S2468-1253(21)00223-5.
46. Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis[J]. Clin Rheumatol, 2018, 37(2): 549-553. DOI: 10.1007/s10067-017-3890-4.
47. Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis[J]. J Rheumatol, 2013, 40(10): 1749-1755. DOI: 10.3899/jrheum.130133.
48. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease[J]. Ann Rheum Dis, 2013, 72(4): 517-524. DOI: 10.1136/annrheumdis-2011-201244.
49. Namba K, Kaburaki T, Tsuruga H, et al. Long-term safety and effectiveness of Adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 patients[J]. Ophthalmol Ther, 2022, 11(3): 1147-1161. DOI: 10.1007/s40123-022-00493-z.
50. Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring[J]. Joint Bone Spine, 2011, 78(Suppl 1): S15-185. DOI: 10.1016/S1297-319X(11)70001-X.
51. 谭雨亭, 侍效春, 刘晓清. 应用肿瘤坏死因子拮抗剂人群结核潜伏感染的检测及预防性治疗[J]. 协和医学杂志, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.Tan YT, Shi XC, Liu XQ. Testing and prophylaxis of latent tuberculosis infection in patients receiving tumor necrosis factor-α antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 86-91. DOI: 10.12290/xhyxzz.20180406.
52. Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2): S10-20. DOI: 10.1016/j.cmi.2017.12.025.
53. 池滢, 杨柳. 关注TNF-α抑制剂在葡萄膜炎治疗中存在的感染和肿瘤发生及进展风险[J]. 中华实验眼科杂志, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.Chi Y, Yang L. Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis[J]. Chin J Pract Ophthalmol, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.
54. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J]. 中华风湿病学杂志, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.Expert Recommendation Group on the Use of Tumor Necrosis Factor Antagonists in Tuberculosis Prevention and Management. Expert consensus on the use of tumor necrosis factor antagonists in tuberculosis prevention and management[J]. Chin J Rheumat, 2013, 17(8): 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002.
55. 王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.Wang GQ, Duan ZP, Wang FS, et al. The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. J Prac Hepatol, 2020, 23(1): 9-32. DOI: 10.3969/j.issn.1672-5069.2020.01.044.
56. 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识(2019)[J]. 中华皮肤科杂志, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.Chinese Medical Association Dermatology and venereology Branch, Chinese Medical Doctor Association Dermatology Branch, Chinese Association of Integrated Traditional and Western Medicine Dermatology and venereology Professional Committee. Treatment of psoriasis with biological agents: a Chinese expert consensus statement (2019)[J]. Chin J Dermat, 2019, 52(12): 863-871. DOI: 10.35541/cjd.20190892.
57. Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies[J/OL]. Front Neurol, 2022, 13: 1003270[2022-09-29]. https://pubmed.ncbi.nlm.nih.gov/36247761/. DOI: 10.3389/fneur.2022.1003270.
58. 李莉, 杨卓, 杨佳, 等. 基于FAERS的阿达木单抗相关不良事件风险信号挖掘[J]. 中国药房, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.Li L, Yang Z, Yang J, et al. Risk signal mining of adverse event related to adalimumab based on FAERS[J]. China Pharmacy, 2022, 33(16): 2006-2011. DOI: 10.6039/j.issn.1001-0408.2022.16.16.

Chinese Journal of Ocular Fundus Diseases

Interpretation of the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content